(Q38561855)

4 September 2017

1 reference

title

Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections? (English)

1 reference

4 September 2017

1 reference

M P Nagata

1

1 reference

4 September 2017

C A Gentry

series ordinal

2

1 reference

4 September 2017

E M Hampton

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 July 1996

1 reference

Annals of Pharmacotherapy

4 September 2017

1 reference

4 September 2017

30

1 reference

4 September 2017

811-818

1 reference

4 September 2017

7-8

1 reference

Amphotericin B therapy in an anephric patient

4 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Amphotericin B Pharmacokinetics in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Pharmacokinetics of amphotericin B and flucytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Antifungal Agents Used in Systemic Mycoses Activity and Therapeutic Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Antifungal susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Correlation between in vitro and in vivo activity of antifungal agents against Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Yeast in blood cultures. Evaluation of factors influencing outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Renal Tubular Acidosis Due to Amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Amphotericin B toxicity. A follow-up report of 53 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Candidemia in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Hepatic candidiasis in cancer patients: the evolving picture of the syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Strategies in the treatment of systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Current role of therapy with amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Current therapy of pulmonary and disseminated fungal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Amphotericin B lipid complex therapy of experimental fungal infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000720

10.1177/106002809603000720

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference